Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis

Gastroenterology

Volumn 124, Issue 5, 2003, Pages 1476-1487

  Häussinger, Dieter ^a   Kordelia Kurz, Anna ^a   Wettstein, Matthias ^a   Graf, Dirk ^a   Vom Dahl, Stephan ^a   Schliess, Freimut ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; FOCAL ADHESION KINASE; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; TAUROURSODEOXYCHOLIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BILE FLOW; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER PERFUSION; MALE; NONHUMAN; OSMOLARITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

EID: 3042594002     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00274-9     Document Type: Article

References (50)

1. Hofmann AF. Pharmacology of ursodeoxycholic acid, an entero-hepatic drug. Scand Gastroenterol Suppl 1994;204:1-15.
2. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16:707-714.
3. Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, Gatzen M, Leuschner M. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989;97:1268-1274.
4. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, LeSage G, Rossi SS, Hofmann AF. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
5. Poupon RE, Balkau B, Eschwege E, Poupon RA. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324:1548-1554.
6. MAPK activation and translocation of the bile salt export pump. Gastroenterology 2001;121:407-419.
7. ++ mechanisms defective in cholestasis. J Clin Invest 1993;92:2984-2993.
8. Häussinger D, Hallbrucker C, Saha N, Lang F, Gerok W. Cell volume and bile acid excretion. Biochem J 1992;288:681-689.
9. Kitani K, Kanai S. Tauroursodeoxycholate prevents taurocholate induced cholestasis. Life Sci 1982;30:515-523.
10. Kurz AK, Block C, Graf D, vom Dahl S, Schliess F, Häussinger D. Phosphoinositide 3-kinase-dependent Ras activation by tauroursodesoxycholate in rat liver. Biochem J 2000;350:207-213.
11. Schliess F, Kurz AK, vom Dahl S, Häussinger D. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver. Gastroenterology 1997;113:1306-1314.
12. Graf D, Kurz AK, Fischer R, Reinehr R, Häussinger D. Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun kinase-dependent manner. Gastroenterology 2002;122:1411-1427.
13. Benz C, Angermuller S, Kloters-Plachky P, Sauer P, Stremmel W, Stiehl A. Effect of S-adenosylmethionine versus tauroursodeoxycholic acid on bile acid-induced apoptosis and cytolysis in rat hepatocytes. Eur J Clin Invest 1998;28:577-583.
14. Güldütuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993;104:1736-1744.
15. Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 1991;100:203-211.
16. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991;14:920-926.
17. Ohiwa T, Katagiri K, Hoshino M, Hayakawa T, Nakai T. Tauroursodeoxycholate and tauro-beta-muricholate exert cytoprotection by reducing intrahepatocyte taurochenodeoxycholate content. Hepatology 1993;17:470-476.
18. Queneau PE, Montet JC. Hepatoprotection by hydrophilic bile salts. J Hepatol 1994;21:260-268.
19. Häussinger D, Saha N, Hallbrucker C, Lang F, Gerok W. Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver. Biochem J 1993;291:355-360.
20. Noe B, Schliess F, Wettstein M, Heinrich S, Häussinger D. Regulation of taurocholate excretion by a hypo-osmolarity-activated signal transduction pathway in rat liver. Gastroenterology 1996;110:858-865.
21. Schmitt M, Kubitz R, Lizun S, Wettstein M, Häussinger D. Regulation of the dynamic localization of the Bsep gene encoded bile salt export pump by anisoosmolarity. Hepatology 2001;33:509-518.
22. +/taurocholate cotransport polypeptide is mediated via the phosphoinositide 3-kinase signaling pathway. J Biol Chem 2000;275:29754-29760.
23. Webster CR, Srinivasulu U, Ananthanarayanan M, Suchy FJ, Anwer MS. Protein kinase B/Akt mediates cAMP- and cell swelling-stimulated Na+/taurocholate cotransport and Ntcp translocation. J Biol Chem 2002;277:28578-28583.
24. Kubitz R, D'Urso D, Keppler D, Häussinger D. Osmodependent dynamic localization of the multidrug resistance protein 2 in the rat hepatocyte canalicular membrane. Gastroenterology 1997;113:1438-1442.
25. Dombrowski F, Kubitz R, Chittattu A, Wettstein M, Saha N, Häussinger D. Electron-microscopic demonstration of multidrug resistance protein 2 (Mrp2) retrieval from the canalicular membrane in response to hyperosmolarity and lipopolysaccharide. Biochem J 2000;348:183-188.
26. Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugte export pump Mrp2 into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 2001;33:1206-1216.
27. Sies H. The use of perfusion of liver and other organs for the study of microsomal electron-transport and cytochrome P-450 systems. Methods Enzymol 1978;52:48-59.
28. Häussinger D, Hallbrucker C, vom Dahl S, Lang F, Gerok W. Cell swelling inhibits proteolysis in perfused rat liver. Biochem J 1990;272:239-242.
29. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette W, Weringer EJ, Pollok BA, Connelly PA. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J Biol Chem 1996;271:695-701.
30. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996;1287:121-149.
31. Tatosyan AG, Mizenina OA. Kinases of the Src family: structure and functions. Biochemistry 2000;65:49-58.
32. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules and selectins. Pharmacol Rev 1998;50:197-263.
33. Chen MB, Grinnell AD. Integrins and modulation of transmitter release from motor nerve terminals by stretch. Science 1995;269:1578-1580.
34. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lckand FynT-dependent T cell activation. J Biol Chem 1996;271:695-701.
35. MAPK in the regulation of proteolysis by liver cell hydration. Gastroenterology 1999;116:921-935.
36. Carloni V, Mazzocca A, Pantaleo P, Cordella C, Laffi G, Gentilini P. The integrin α6β1 is necessary for the matrix-dependent activation of FAK and MAPK and the migration of human hepatocellular carcinoma cells. Hepatology 2001;34:42-49.
37. Hsu SL, Cheng C, Shi YR, Chiang CW. Proteolysis of integrin α5 and β1 subunits involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. Cancer Lett 2001;167:193-204.
38. Torimura T, Ueno T, Kin M, Harada R, Nakamura T, Kawaguchi T, Harada M, Kumashiro R, Watanabe H, Avraham R, Sata M. Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of β1 integrins. Hepatology 2001;34:62-71.
39. Withers BE, Hanks SK, Fry DW. Correlations between the expression, phosphotyrosine content and enzymatic activity of focal adhesion kinase, pp125FAK in tumor and non-transformed cells. Cancer Biochem Biophys 1996;15:127-139.
40. Cobb BS, Schaller MB, Leu T, Parsons JT. Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase pp125FAK. Mol Cell Biol 1994;14:147-155.
41. Schlaepfer DD, Hanks SK, Hunter T, van der Geer P. Integrinmediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 1994;372:786-791.
42. Schlaepfer DD, Hunter T. Focal adhesion kinase overexpression enhances Ras-dependent integrin signaling to Erk2/mitogen-activated protein kinase through interactions with and activation of c-Src. J Biol Chem 1997;272:13189-13195.
43. Chen HC, Appeddu PA, Isoda H, Guan JL. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol-3-kinase. J Biol Chem 1996;271:26329-26334.
44. Chen Q, Kinch MS, Lin TH, Burridge K, Juliano RL. Integrin-mediated cell adhesion activates mitogen-activated protein kinases. J Biol Chem 1994;269:26602-26605.
45. + exchangers. J Biol Chem 1999;274:8093-8102.
46. Abe J, Okuda M, Huang Q, Yoshizumi M, Berk BC. Reactive oxygen species activate p90 ribosomal S6 kinase via Fyn and Ras. J Biol Chem 2000;275:1739-1748.
47. Xu LH, Owen LV, Sturge GC, Yang X, Liu ET, Craven RJ, Cance WG. Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 1996;7:413-418.
48. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-687.
49. Ingber DE. Tensegrity: the architectural basis of cellular mechanotransduction. Annu Rev Physiol 1997;59:575-599.
50. Lin TH, Aplin AE, Shen Y, Che Q, Schaller M, Romer L, Aukhil I, Juliano RL. Integrin-mediated activation of MAPK is independent of FAK: evidences for dual integrin signaling pathways in fibroblasts. J Cell Biol 1997;136:1385-1395.